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Recent experiments have suggested that the infectivity of simian immunodeficiency virus
(SIV) and human immunodeficiency virus type-1 (HIV-1) in plasma decreases over time
during primary infection. Because anti-gp41 antibodies are produced early during HIV-1
infection and form antibody-virion complexes, we studied if such early HIV-1 specific
antibodies are correlated with the decay in HIV-1 infectivity. Using a viral dynamic model
that allows viral infectivity to decay and frequent early viral load data obtained from 6
plasma donors we estimate that HIV-1 infectivity begins to decay after about 2 weeks
of infection. The length of this delay is consistent with the time before antibody-virion
complexes were detected in the plasma of these donors and is correlated (p = 0.023,
r = 0.87) with the time for antibodies to be first detected in plasma. Importantly, we
identify that the rate of infectivity decay is significantly correlated with the rate of increase
in plasma anti-gp41 IgG concentration (p= 0.046, r = 0.82) and the increase in IgM+IgG
anti-gp41 concentration (p = 8.37 × 10−4, r = 0.98). Furthermore, we found that the
viral load decay after the peak did not have any significant correlation with the rate of
anti-gp41 IgM or IgG increase. These results indicate that early anti-gp41 antibodies may
cause viral infectivity decay, but may not contribute significantly to controlling post-peak
viral load, likely due to insufficient quantity or affinity. Our findings may be helpful to devise
strategies, including antibody-based vaccines, to control acute HIV-1 infection.
Keywords: antibodies, primary HIV-1 infection, viral dynamics model, viral load, virus infectivity
INTRODUCTION
Primary human immunodeficiency virus type 1 (HIV-1) infection is associated with an initial
eclipse phase, during which the viral load remains below the limit of detection of conventional
assays, followed by a rapid viral load increase (Daar et al., 1991; Schacker et al., 1996; Fiebig et al.,
2003; Ribeiro et al., 2010; Cohen et al., 2011). After the viral load reaches its peak, it declines and
reaches a set-point level (i.e., a quasi-steady state). The early events during primary HIV-1 infection
not only have particular relevance for vaccine, microbicide and pre/post-exposure prophylaxis
(Chun et al., 1998; Pope and Haase, 2003; Shattock and Moore, 2003; Haase, 2005), they are also
important in defining the set-point viral load later in infection (Lifson et al., 1997) and the time
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period over which a successful vaccine needs to induce a
protective response prior to establishment of the latent pool
of HIV-1 infected CD4+ T cells (Wong and Siliciano, 2003;
Johnston and Fauci, 2007).
Based on a previous experiment involving simian
immunodeficiency virus (SIV) infection of macaques that
revealed a difference in infectivity between virus in plasma
obtained 7 days after infection and set-point virus (Ma
et al., 2009), we introduced an SIV dynamic model with time-
dependent viral infectivity (Vaidya et al., 2010). Also, preliminary
data comparing the ratio of the 50% tissue culture infectious dose
(TCID50) with HIV-1 RNA copy number suggests a decrease in
virus infectivity over time during primary infection in HIV-1
infected patients, although the magnitude of this effect varies
among subjects (Genevieve Fouda and David Montefiori, Duke
University School of Medicine, unpublished data). Although
the mechanisms responsible for the decay in viral infectivity
have not been established, it has been speculated that binding
of antibodies to HIV-1 might be in part responsible (Ma et al.,
2009). Consistent with this, during early HIV-1 infection it has
been shown that anti-gp41 antibodies are produced and form
virion-antibody complexes (Tomaras et al., 2008; Liu et al.,
2011).
Here we sought to determine whether these early anti-gp41
antibodies influence HIV infectivity by fitting a mathematical
model to frequently measured plasma viral loads obtained from 6
plasma donors. Themodel, which incorporates a time-dependent
infectivity rate, fits the acute infection HIV-1 data well. We
show the infectivity decay predicted by our model significantly




Sequential HIV-1 viral load data from 6 plasma donors was
obtained as previously described (Gasper-Smith et al., 2008;
Tomaras et al., 2008; Stacey et al., 2009). The study was approved
by the Duke Health Institutional Review Board, protocol number
Pro00006579. Each individual donated 600–800ml of plasma
which was frozen within 8 h to −20◦C or less. The plasma
samples were stored up to 2 months then sent in pools to
be serologically screened for HIV. Donors who were HIV-1
positive were notified and deferred from subsequent donation.
HIV-1 positive samples were aliquoted, and refrozen at −20◦C.
Aliquoted samples of plasma donors were quantified with
the Roche Amplicore HIV-1 RT PCR Ultra assay by Quest
Diagnostics (Lyndhurst, NY), with a lower limit of quantification
of 50 HIV-1 RNA copies/ml (Tomaras et al., 2008). There was a
median of 9 data points per donor with a median of 4 data points
before the viral peak. The median peak viral load was 6.0 (range
4.5–6.8) log10 viral RNA (vRNA) copies/ml. In these plasma
donors, the anti-gp41 IgG and IgM responses were also measured
and recorded as optical density (O.D.) (Tomaras et al., 2008).
In addition, circulating antibody-virion immune complexes were
measured (Tomaras et al., 2008; Liu et al., 2011). The data
analyzed below is provided in Table S1.
Viral Dynamic Model
To study the effect of antibody responses in decreasing viral
infectivity early during infection, we use the standard model of
viral infection (Phillips, 1996; Nowak et al., 1997; Little et al.,
1999; Perelson and Nelson, 1999; Stafford et al., 2000), but allow
the virus infectiousness to decay in time after a certain delay τ ,
which accounts for the time needed to generate an anti-HIV-1
response. The model is
dT
dt
= λ − dT − β (t)TV , T (0) = T0,
dI
dt
= β (t)TV − δI, I (0) = I0,
dV
dt




β0, t ≤ τ ,
β∞ + (β0 − β∞) e
−k(t−τ ), t > τ .
(2)
The model consists of target cells (CD4+ T cells), T, productively
infected CD4+ T cells, I, and free virus, V . We assume that
target cells are generated at a constant rate λ, have a per capita
net loss rate d, which is the difference between loss from cell
death and gain due to cell division, and become infected at a
rate proportional to the product of target cell density and virus
concentration with a time-dependent rate β(t). The parameters
δ, p, and c are the rate constants of infected cell loss, virus
production by infected cells and virus clearance, respectively. As
in Vaidya et al. (2010), we assume a simple exponential decay in
infectivity over time from the initial rate β0 to the final rate β∞
with a decay rate k, but for a more general formulation here we
include a time-delay τ before infectivity decay begins.
Data Fits and Parameter Estimation
We fit the model, Equations (1) and (2), to plasma viral load
data obtained from 6 HIV-1-infected plasma donors during the
acute phase of infection. Earlier studies have shown that the
percentage of proliferating CD4+ T cells in the peripheral blood
of healthy individuals, as measured by Ki-67 antigen expression,
is ∼1% (Sachsenberg et al., 1998). We use Ki-67+ CD4+ cells as
a surrogate for target cells and thus take the initial number of
target cells, T0, as 10
4 per ml (1% of 106/ml CD4+ T cell count).
We note that, as in Stafford et al. (2000), the model system (1)
becomes independent of T0 if the scaling p → p/T0 is performed.
This shows that taking the value of T0 different from 10
4 per ml
affects the estimates of only p, not the infectivity rate, β (t), and
thus, our conclusions will remain unaffected if one uses other
values of T0. Assuming CD4
+ T cells were at equilibrium before
infection, we set λ = dT0. Because the route of infection of
the plasma donors is not known, we first assumed infection was
initiated by free virus particles rather than infected cells, and thus
we set I0 = 0 (Pearson et al., 2011). Then we also analyzed the
data assuming infection was initiated by an infected cell. Recent
estimates show that the virion clearance rate constant, c, varies
between 9.1 day−1 and 36.0 day−1, with an average of 23 day−1
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(Ramratnam et al., 1999). Thus, we take c = 23 day−1, although
other values in this range were also considered in a sensitivity
analysis.
It is difficult to obtain information about the initial virus
concentration that established infection. At least one virion, i.e.,
2 viral RNA (vRNA) copies, is needed to establish infection. A
70-kg person has about 15 L of extracellular body water and
about 3 L of plasma. Thus, the initial plasma viral load needed
to establish systemic infection is >2 vRNA copies per 3,000ml
or >2 vRNA copies per 15,000ml depending upon whether
the virus distributes throughout only the plasma or the total
extracellular body water before initiating infection. Here, we
present results withV0 = 10
−3 vRNA copies perml assuming that
the virus distributes in the plasma and then study the sensitivity
of parameter estimates on the initial viral load (V0) by varying
V0 from 10-fold lower considering the possibility of virus being
distributed through extracellular body water to 1,000-fold higher
corresponding to the possibility of much higher levels of virus
initially entering the circulation.
The exact time of initial infection is not available for this data
set. However, the initial viral expansion rates for these subjects
have been estimated in a previous study (Ribeiro et al., 2010).
Using the slope of viral increase estimated in Ribeiro et al. (2010)
and the base value of V0, we calculated the time of infection and
then the time to the first measured viral load above the detection
limit for each of these subjects. This allowed us to associate a time
since infection with each data point. To estimate τ , we varied τ
in 1 day increments, and chose the one which provided the best
fit for each plasma donor. The other 6 parameters, β∞, β0, k, δ,
d, and p, were kept free and estimated by fitting the model to
the data from each plasma donor. We also performed fitting by
making τ a free parameter and obtained approximately the same
value as the best estimate from 1-day increment fitting. Since
the fit was not improved with τ as an extra free parameter, we
fixed τ as the best estimate obtained from the 1-day increment
fitting.
Parameter identifiability in HIV models, including those with
time-varying parameters, was discussed in Wu et al. (2008) and
Miao et al. (2011). As shown in Miao et al. (2011) and Wu et al.
(2008), with λ fixed as in our case, all the constant parameters
are structurally identifiable. Miao et al. (2011) showed that the
time-varying parameter (β (t) in our case) is also identifiable if
all the constant parameters are identifiable. Therefore, we expect
that the parameters of our model are identifiable for the number
of data points available in this study.
The data fitting protocol used to estimate parameters was
as described previously in Vaidya et al. (2010). We solved the
system of ordinary differential equations (ODEs) numerically
using a fourth-order Runge-Kutta in Berkeley Madonna. Using
Madonna’s “curve fitter” option, we obtain a set of initial
parameter estimates. The curve fitting method uses nonlinear













log10 V(ti)− log10 V(ti)
]2
. (3)
Here, V and V are virus concentrations predicted by the model
and those given by the experimental data, respectively. N is the
total number of data points.
Using the set of parameters obtained from Madonna as
initial guesses, we refined the fits by using “fmincon.m”
and/or “fminsearch.m” functions in MATLAB. For each best fit
parameter estimate, we provide a 95% confidence interval (CI),
which was computed from 500 bootstrap replicates (Efron and
Toibshirani, 1986). Since we analyze only 6 subjects, we present
results as medians and ranges, unless otherwise indicated.
Sensitivity Analysis
The viral load establishing systemic infection, V0, is not known.
To study the sensitivity of our results to the choice of V0, we
randomly selected 200 different V0 from 10-fold lower (i.e., 10
−4
vRNA copies/ml) to 1,000-fold higher (i.e., 1 vRNA copies/ml)
and estimated parameters for each of the 6 donors.
Statistical Analysis
We performed linear regression to obtain the slope of the
IgG increase, the IgM increase and the IgG+IgM increase. We
then carried out correlation analyses using Pearson’s correlation
between these slopes and the decay slope of infectivity estimated
by our model. We also calculated the slope of the viral load decay
after the peak and performed correlation analyses of the viral
decay rate with the antibody response.
To evaluate the statistical significance of models comparisons,
we performed an F-test (Bates and Watts, 2007) as the models
considered in this study without and with infectivity decay are
nested.
RESULTS
Model Fitting to Data
We fitted Equations (1) and (2) to the HIV-1 data. We estimated
six parameters β∞, β0, k, δ, d, and p from the data fitting. The
estimated parameters along with their 95% confidence intervals
are summarized in Table 1. Using these estimated parameters,
we plotted the viral load dynamics predicted by the model along
with the data for each of the 6 HIV-1 infected plasma donors in
Figure 1. The predictions of our time-varying infectivity delay
model (solid curve) agree well with the data (filled circles).
For comparison, we also fitted these viral load data using a
constant infectivity (i.e., β(t) constant) model (Stafford et al.,
2000), and found that the delay model with time-dependent
infectivity provides statistically significant better fits (p = 0.001,
F-test with all the subjects combined as in Vaidya et al., 2010).
Moreover, we compared the data fitting using a time-dependent
model without delay (Vaidya et al., 2010) (i.e., τ = 0), and found
that including a delay in the model significantly improved the fits
(p= 0.008, F-test, Vaidya et al., 2010).
Virus Infectivity Decay
We estimated the median initial and late viral infection rate
constants to be β0 = 4.20 × 10
−7 ml RNA−1 day−1 and
β∞ = 0.76 × 10
−7 ml RNA−1 day−1, respectively (Table 1).
This suggests that infectivity decays during acute HIV-1 infection
Frontiers in Microbiology | www.frontiersin.org 3 June 2018 | Volume 9 | Article 1326





































































































































































































































































































































































































































































































































































































































































































































































































(p = 0.031, paired Wilcoxon Test). Such infectivity decay over
time was also observed previously in SIV infection (Ma et al.,
2009; Vaidya et al., 2010). Assuming that the decay of β(t) occurs
exponentially with rate k, we found that HIV-1 infectivity decays
with amedian rate of k= 0.049 day−1 (Table 1) (range: k= 0.013
day−1 to k = 0.249 day−1). Also, the time, th, to reduce the virus
infectivity to its mid-value, (β0 + β∞)/2, given by ln (2) /k, was
found to be 21 days (Table 1).
Correlation of Infectivity With Antibody
Response
It is known that antibodies bind to virions and form antibody-
virion complexes (Dianzani et al., 2002; Tomaras et al., 2008; Liu
et al., 2011). Such antibodies bound to virions might interfere
with the infection process (Ma et al., 2009). Therefore, we
examined if there is any correlation between the infectivity
decay and the earliest antibody responses detected during acute
infection, i.e., the anti-gp41 IgM and/or IgG response (Tomaras
et al., 2008; Liu et al., 2011).
While we acknowledge some uncertainty due to sparsity in
early Ab data, in general, as shown in Figure 2, the anti-gp41
IgM concentration (measured in optical density. i.e., O.D. units)
increases approximately linearly up to a maximum value and
then decays, whereas the anti-gp41 IgG concentration increases
monotonically over the time period studied. This pattern of IgM
increasing and then decreasing is consistent with the known
features of the IgM-IgG isotype switch (Murphy et al., 2008). We
performed a linear regression analysis to find the slope of the IgM
increase, of the IgG increase and of the IgM+IgG increase using
the antibody data to the time point where antibody levels saturate
or start to decay. The IgM and IgG concentrations increase by a
median rate of 0.19 day−1 and 0.09 day−1, respectively, while the
median rate of increase in the IgM + IgG concentration is 0.27
day−1 (Table S2).
While there was a positive association between the rate of
infectivity decay estimated by our model (k) and the slope of
IgM increase (Figure 3), this correlation was not statistically
significant (p = 0.33, r = 0.48). However, we found that the
rate of infectivity decay has a statistically significant positive
correlation with the slope of IgG increase (p = 0.046, r = 0.82)
and a very significant positive correlation with the IgM+IgG
anti-gp41 concentration with p-value = 8.37 × 10−4 and r-
value= 0.98 (Figure 3). This suggests that the antibody response
might contribute to the loss of virus infectivity. To check the
robustness of this finding, we performed correlation analysis by
iteratively excluding each donor one at a time, and found that the
correlation of infectivity decay with slope of increase of IgM+IgG
remained statistically significant (p< 0.01 in each case, Table S3).
The Delay Before the Start of Infectivity
Decay Correlates With the Time Until the
Antibody Response Is Detected
Our model predicts that the virus infectivity begins to decay
after a median time of 11 days (range: 5–24 days) of infection.
The exact delay from the time of infection to the initiation of
antibody increase is not known. However, from the experimental
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FIGURE 1 | Fitted viral dynamics curve using the delay model with time-varying infectivity to the observed viral load data (filled circle) during primary infection of 6
HIV-1 infected plasma donors.
data we estimated the time from infection (as estimated by our
calculation) to the time when the free IgM+IgG level begin
to increase in plasma. In the donated plasma, antibodies were
measured and, in every case, O.D. readings of both IgM and IgG
began to increase on the same day. Since the antibodies were
assayed in every sample, we defined the time when antibody
becomes detectable as the first time point for which the O.D. of
IgM+IgG level was above the limit of detection (i.e., O.D. > 0.5).
We found a statistically significant correlation (p = 0.0233,
r = 0.87) between the time that antibody became detectable in
plasma and the delay before infectivity decay began predicted by
our model (Figure 4). Furthermore, for three donors (CHID77,
CHID08, CHID79), the times for antibody-virion complexes to
be experimentally detectable in plasma were reported previously
as 13, 9, and 6 days, respectively, where this was measured
relative to the time at which the plasma viral load first reached
100 copies/ml (Tomaras et al., 2008). Using the eclipse phase
of acute infection in these plasma donors, calculated from the
slope of viral increase estimated in Ribeiro et al. (2010), these
times translate to 24, 18, and 14 days from the time of infection.
These values and their rank-order are consistent with the delay
for infectivity decay predicted by our model (24, 22, 10 days,
respectively, Table 1).
Correlation of Post-peak Viral Load Drop
With Antibody Response
To observe if antibodies have any significant impact on viral
load decay after the viral load peak, we performed a correlation
analysis between the slope of IgM increase, IgG increase,
IgM+IgG increase and the slope of the viral load drop after the
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FIGURE 2 | Anti-gp41 IgM, IgG and (IgM+IgG) antibody response data during primary infection from 6 HIV-1 infected plasma donors. The lines represent the best fits
used to estimate the upward slope of the antibody increase.
peak (Table S2). We did not find any significant correlation with
IgM, IgG or IgM+IgG indicating that this antibody response
might not be the primary cause for the drop of viral load after
the peak, consistent with previous findings (Tomaras et al., 2008).
In our viral dynamic model, Equation (1), viral load drop after
the peak is due to target cell limitation and death of productively
infected cells.
Sensitivity Analysis
Above we analyzed the correlation of two parameters, k and τ ,
with the antibody response. We estimated these parameters by
fitting our model to viral load data. Due to lack of information
about the actual number of virions initiating infection, V0, we
assumed V0 = 10
−3 vRNA copies/ml. To ensure that the choice
of V0 did not bias our results, we re-fit the data taking 200
different values of V0 selected randomly from 10-fold lower to
1,000-fold higher (i.e., 10−4 to 1) than the base-case. We find
that the estimate of τ is not affected at all, and that the median
change in the estimates of k is below 5% (Figure S1). Therefore,
our results are not sensitive to the choice of V0.
We assumed that the infection was initiated with free virus
particles. To study how the estimates are affected if the infection
was initiated with infected cells, we compared the estimates
between an infection with one virus particle distributed in 15 L
body water (i.e., V0 = 2/15000 vRNA copies/ml) and an
infection with one infected cell distributed in 15 L body water
(i.e., I0 = 1/15000 cells/ml). We found that the estimates of k
are essentially the same in these two cases (Figure S2).
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FIGURE 3 | Correlation analysis of the slope of experimentally measured IgM, IgG and (IgM+IgG) antibody increase with the rate of infectivity decay predicted by our
model.
FIGURE 4 | Correlation analysis between the time for total antibody (IgM+IgG)
response to be experimentally detectable in plasma and the delay for the start
of infectivity decay predicted by our model.
We chose c = 23 d−1 based on the average of the
experimentally estimated range between 9 and 36 d−1. To test the
robustness of our results to this assumption, we refitted the data
with different values of c within this range. The only parameters
that is mainly affected is the viral production rate. Therefore, our
results regarding k and τ are not affected by the specific value of c.
DISCUSSION
During primary HIV-1 infection, a decay of virus infectivity
over time has been suggested by comparing the ratio of tissue
culture infectious dose (TCID50) with HIV RNA copy number
in sequential early viral load samples from a limited number of
subjects (Genevieve Fouda and David Montefiori, unpublished
data). In addition, HIV-1-specific anti-gp41 antibodies have been
detected in plasma amedian of 13 days after the viral load reaches
100 vRNA copies/ml (Tomaras et al., 2008). Moreover, anti-gp41
IgM-virion or IgG-virion complexes were found as early as 5
days after the viral load became detectable (Tomaras et al., 2008;
Liu et al., 2011). The presence of such antibodies might affect
the infectivity of HIV-1 (Tomaras et al., 2008; Ma et al., 2009).
Therefore, one of the main objectives of this study was to ask
if there is a correlation between the infectivity decay of plasma
virus and the anti-gp41 antibody response in HIV-1 infected
individuals.
Since there are delays before antibodies and antibody-virion
complexes become detectable in plasma (Tomaras et al., 2008),
we extended a previous infection model (Vaidya et al., 2010)
used to study acute SIV infection by incorporating a time-delay
before infectivity decay begins. We then used this delay model to
quantify the time-variation of HIV-1 infectivity during primary
infection. Our data fitting procedure reveals that both time-
dependent nature and delay of infectivity decay are necessary to
better describe the viral load data from primary HIV-1 infection.
According to our model estimates, plasma HIV-1 infectivity
decays exponentially with a median rate of 0.049 day−1 (Table 1),
and there is a time delay of about 2 weeks (range 5–24 days)
before virus infectivity begins to decay. The length of this delay
is consistent with the period from infection to the time when
the virion-antibody complexes were detected in plasma (Tomaras
et al., 2008), and is significantly correlated (p= 0.0233, r = 0.87)
with the time post-infection for anti-gp41 antibody (IgG+IgM)
to be detectable in plasma (Figure 4).
Our analyses also showed a statistically significant and strong
correlation between the rate of increase of the IgM+IgG anti-
gp41 antibody concentration and the rate of infectivity decay
estimated by the model (p= 0.0008, r= 0.98) (Figure 3). On the
other hand, we did not observe a significant correlation between
the slope of the IgM, IgG or IgM+IgG increase and the slope of
viral load drop after the viral load peak. Taken together, these
results indicate that the anti-gp41 (IgM+IgG) response might
contribute to the reduction of virus infectivity, but that these
anti gp41 antibodies have minimal effect on controlling post peak
viral load as seen in Tomaras et al. (2008). Thus other factors,
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such as target cell limitation (Stafford et al., 2000) and cytotoxic
T cell responses (Goonetilleke et al., 2009) may be playing a
role in determining the post-peak viral decline. Because cells
are not collected from plasma donors quantifying the change in
target cell levels and the magnitude of the CTL response was not
possible in this study.
A contribution of antibodies to reducing viral infectivity was
suggested by Ma et al. (2009), and supported by their observation
that mixing plasma obtained at set-point with plasma obtained
7 days after SIV infection reduced the infectivity of the 7-
day plasma. However, our inference that antibody affects the
infectivity of HIV-1 during early infection is derived from a
correlation based on limited viral load and antibody data from
only 6 individuals. We cannot rule out other possible causes
of infectivity decay such as the production of non-infectious
viral genomes that reduce infectivity, as the virus that founds
the infection diversifies due to mutation during early infection,
or other plasma proteins binding to virions and mediating
infectivity decay. Also, the correlation between the slope of
the infectivity decay and the up-slope of antibody responses
obtained in this study is for the early stages post-infection. Once
a plasma donor was identified as being HIV+ donations were
stopped and hence no long-term data were collected. Later in the
infection antibody responses saturate or decay. To capture the
long-term effect, the model needs to be extended to incorporate
such behavior and longer-term data is needed to validate such
extended models.
While this study supports the hypothesis that antibodies
reduce viral infectivity, we acknowledge that antibodies might
have other anti-HIV effects, such as enhanced virion clearance
and/or antibody-dependent cellular cytotoxicity (Tomaras and
Haynes, 2009, 2010). However, these effects were found to have
negligible contribution to HIV-1 viral dynamics (Tomaras et al.,
2008). In our previous study, we (Tomaras et al., 2008) also
investigated the effects of antibody in neutralizing virus by
reducing the infectivity rate in a mathematical model including
antibody data, but we did not find a significant antibody effect
in most patients. The difference with the current results could be
due to differences in the two modeling approaches: the delay in
the antibody effect in Tomaras et al. (2008) was entirely given
by the free antibody data, i.e., the delay corresponded to the
time delay for antibody to become detectable in plasma, while
the delay in our model (estimated to be much shorter, Figure 4)
corresponds to the delay for the formation of antibody-virion
complexes. Note that antibody-virion complexes are detectable
earlier than free antibodies in plasma (Tomaras et al., 2008).
The second difference in the two modeling approaches is the
functional form of the infectivity decay introduced into the
models (see Text S1). A study with more antibody data may
help to accurately and explicitly incorporate antibody effects
into viral dynamic models. While direct comparison between
these two models might not be appropriate as our model does
not have explicit dynamics for antibodies, clarifying these issues
might be important for future development of models that take
explicit antibody responses into account. We also acknowledge
uncertainty in the route of infection and the actual time of
infection; if the time of initial infection is different, then this may
imply a different dose of infecting virus, or even differences in
host immune response to the virus infection. However, we note
that it is very difficult to find HIV infected individuals so early
in infection. This complexity makes this data set unique and
highlights the importance of this study.
Although our model cannot conclusively address the causes
of decay in HIV-1 infectivity, the quantitative agreement
between our model’s predictions and the measured viral
load curves in all 6 subjects, and the correlation of the
rate of infectivity decay with the measured increase in
anti-gp41 antibody concentrations strongly suggest the
early anti-HIV-1 response, even though non-neutralizing
may still provide benefit. More data, especially on early
antibody responses (including IgA responses), the formation
of antibody-virion complexes, and the ratio of infectious
virus to total HIV-1 RNA are needed to provide a more
accurate picture of virus infectivity during primary HIV-1
infection.
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